Biofrontera Inc. Announces Record Preliminary Q4 2025 Revenues, Exceeding $17M with Strong YOY Growth
Summary
Biofrontera Inc. announced preliminary record revenues for the fourth quarter of 2025, ranging from $17.0 million to $17.5 million, alongside strong double-digit full-year growth.
Key Events
-
Record Quarterly Revenue
Preliminary unaudited revenues for Q4 2025 are projected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the company's history.
-
Strong Year-Over-Year Growth
The Q4 2025 revenue figures reflect approximately 35% to 39% year-over-year growth, primarily driven by sales execution of Ameluz®.
-
Positive Full-Year Performance
Full year 2025 revenues are expected to be in the range of $41.5 million to $42.0 million, indicating double-digit growth of 11% to 13% year-over-year.
-
Strategic Foundation Strengthened
Management noted that a recent transformational transaction with Biofrontera AG is expected to meaningfully improve the gross margin profile and strengthen the financial foundation.
Analysis
Biofrontera Inc. reported preliminary unaudited revenues for Q4 2025 between $17.0 million and $17.5 million, marking the highest quarterly revenue in the company's history. This represents significant year-over-year growth of approximately 35% to 39%. For a company with a market capitalization of under $10 million, these revenue figures are exceptionally strong and indicate robust operational performance. The CEO highlighted strong execution, continued growth of Ameluz® PDT, and a recent transformational transaction with Biofrontera AG that is expected to improve gross margin and strengthen the financial foundation. This positive update could significantly re-rate the company's valuation and investment thesis.
At the time of this filing, BFRI was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.54 to $1.24. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.